Table 2.
Comparison of the results of differential parameters and lymphocyte cellular population data in 137 controls, 322 patients with proven COVID infection, and 285 patients for whom investigations were negative for SARS‐CoV‐2 infection (COVID−)
| Controls | COVID + | COVID− | Optimal cutoff | AUC [95% CI] | |
|---|---|---|---|---|---|
| NE (×109/L) | 4.9 [1.7‐7.3] | 4.6 [0.6‐17.3] | 5.6 [0‐27.18] | ≤4.4 | 0.594 [0.555‐0.633] |
| EO (×109/L) | 0.1 [0‐0.5] | 0 [0‐0.9] | 0.1 [0‐1] | ≤0 | 0.716 [0.678‐0.752] |
| LY (×109/L) | 1.9 [1‐3.9] | 0.9 [0.1‐12.4] | 1.3 [0.1‐17.1] | ≤1.1 | 0.688 [0.650‐0.725] |
| MO (×109/L) | 0.5 [0.2‐1] | 0.5 [0.1‐7] | 0.6 [0‐11.5] | ≤0.4 | 0.626 [0.587‐0.665] |
| SD‐MALS‐NE | 10.4 [8.3‐16.7] | 10.2 [8.7‐17.3] | 10.8 [8.6‐43.5] | ≤10.43 | 0.622 [0.582‐0.661] |
| MN‐UMALS‐NE | 139 [124‐152] | 143 [116‐158] | 141 [118‐155] | >139 | 0.62 [0.58‐0.659] |
| SD‐LMALS‐NE | 13.2 [10.4‐25.5] | 12.7 [10.3‐24.6] | 13.6 [10.5‐40.7] | ≤12.68 | 0.609 [0.569‐ 0.648] |
| SD‐LALS‐NE | 32.1 [25.6‐53.1] | 30.5 [23.4‐57.8] | 32.2 [25.1‐57.5] | ≤31.46 | 0.604 [0.564‐0.643] |
| SD‐V‐LY | 14 [11.3‐24.3] | 16.5 [11.6‐36.5] | 14.6 [9.7‐31.2] | >15.07 | 0.689 [0.651‐0.726] |
| SD‐C‐LY | 7.5 [5.4‐10.9] | 8.9 [5.7‐26.8] | 8 [4.6‐28.9] | >8.15 | 0.612 [0.572‐0.651] |
| SD‐MALS‐LY | 16.3 [13‐23] | 17.7 [13.5‐35.4] | 16.3 [12.8‐39] | >16.36 | 0.664 [0.625‐0.702] |
| SD‐UMALS‐LY | 20 [16.2‐26.6] | 21.6 [15.4‐37.1] | 20 [14.6‐40.7] | >21.18 | 0.658 [0.618‐0.695] |
| SD‐LMALS‐LY | 18.3 [14.6‐24.4] | 19 [15.5‐33.6] | 18.2 [15‐40.1] | >18.61 | 0.63 [0.59‐0.669] |
| SD‐AL2‐LY | 12.6 [11.1‐14.5] | 13.8 [11.4‐18.9] | 13.2 [10.8‐24.9] | >13.35 | 0.661 [0.622‐0.699] |
| MN‐V‐MO | 175 [153‐214] | 187 [166‐228] | 177 [152‐229] | >180 | 0.742 [0.705‐0.777] |
| SD‐V‐MO | 19.1 [15.6‐35.1] | 24.8 [16.8‐33.6] | 20.3 [14.5‐41.6] | >21.71 | 0.819 [0.786‐0.849] |
| MN‐C‐MO | 122 [110‐129] | 124 [115‐133] | 123 [111‐132] | >123 | 0.613 [0.573‐0.652] |
| SD‐MALS‐MO | 10.8 [8.8‐13.7] | 11.4 [8.8‐18.2] | 10.9 [8‐25.6] | >11.31 | 0.611 [0.571‐0.650] |
| SD‐UMALS‐MO | 12.3 [9.2‐27.9] | 13.9 [9.2‐27.7] | 12.4 [8.8‐31.3] | >12.85 | 0.65 [0.611‐0.688] |
| SD‐LMALS‐MO | 14 [11.6‐18.6] | 15 [10.5‐20.5] | 14.4 [10.1‐26.1] | >14.08 | 0.611 [0.571‐0.65] |
| SD‐LALS‐MO | 27.8 [17.1‐39.9] | 29.3 [21‐43.3] | 27.5 [15.9‐47] | >24.71 | 0.62 [0.58‐0.659] |
| MN‐AL2‐MO | 106 [87‐147] | 141 [93‐162] | 137 [3‐161] | >145 | 0.611 [0.571‐0.65] |
| SD‐AL2‐MO | 17.1 [.6‐26.2] | 19.7 [11.8‐30] | 17.4 [10.9‐38.5] | >17.51 | 0.722 [0.684‐0.757] |
Results are expressed as the median and [range]. CPD are expressed as arbitrary units. For all the parameters presented in this table, P between COVID+ and COVID– patients were <.0001 (Mann‐Whitney test).
Abbreviations: AUC, area under the curve; CI, confidence interval.